BRD9 was amplified in bladder cancer (10.17%), lung squamous cell carcinoma (19.37%), lung adenocarcinoma (15.02%), esophageal carcinoma (14.52%) and ovarian cancer (13.53%). Here, BRD9 is linked to urinary bladder carcinoma.